Talphera to Showcase Niyad for CRRT in Investor Event
Event summary
- Talphera to host virtual investor event on March 23, 2026, to discuss Niyad for CRRT.
- Event features key opinion leaders Blaithin McMahon and Joao Teixeira as presenters.
- Niyad is a lyophilized form of nafamostat, targeting CRRT patients intolerant to heparin.
- NEPHRO CRRT study is a prospective, double-blinded trial with 70 adult patients.
- FDA granted Breakthrough Device Designation to Niyad for CRRT anticoagulation.
The big picture
Talphera's focus on Niyad for CRRT addresses a critical unmet need in anticoagulation for high-risk patients. The event underscores the strategic shift toward specialized therapies in intensive care settings, where current options like heparin and citrate have significant limitations. The company's progress could reshape the CRRT market, particularly if the NEPHRO CRRT study delivers positive results.
What we're watching
- Regulatory Pathway
- Whether the Breakthrough Device Designation will accelerate Niyad's approval process.
- Clinical Success
- The efficacy and safety data emerging from the NEPHRO CRRT study.
- Market Adoption
- The pace at which Niyad could displace heparin and citrate in CRRT settings.
Related topics